Neurocrine Biosciences shares drop on Vykat safety concerns

Shares of Neurocrine Biosciences fell on Wednesday after U.S. regulators flagged potential safety concerns related to Vykat, the company’s experimental epilepsy treatment.

The U.S. Food and Drug Administration (FDA) issued a partial clinical hold on Vykat, citing safety issues that require further evaluation. The regulator’s decision follows an interim analysis of trial data, though the specific concerns were not detailed in the announcement.

Neurocrine Biosciences did not disclose additional information about the FDA’s concerns or the scope of the clinical hold. The company stated it is working with regulators to address the issues and provide further clarity in due course.

Vykat, also known as VX-150, is being developed as an adjunctive therapy for focal seizures in adults with epilepsy. The treatment is part of Neurocrine’s broader neurology pipeline, which includes other investigational therapies for neurological disorders.

The FDA’s partial clinical hold does not constitute a complete halt to the trial but requires Neurocrine to pause enrollment and dosing in new patients until the safety concerns are resolved. Existing patients already receiving Vykat may continue treatment under modified protocols, pending regulatory guidance.

Analysts noted that while the clinical hold introduces near-term uncertainty, Vykat remains a key asset for Neurocrine, with potential peak sales estimates exceeding $500 million annually if approved. The company’s shares have historically been sensitive to clinical trial updates, particularly for its neurology-focused pipeline.

Neurocrine Biosciences is scheduled to report its next quarterly earnings on May 2. Investors will be closely monitoring updates on Vykat’s regulatory pathway and any further disclosures from the company regarding the FDA’s concerns.